Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial

BACKGROUND: Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Celina, Gibani, Malick M, Moore, Maria, Juel, Helene B, Jones, Elizabeth, Meiring, James, Harris, Victoria, Gardner, Jonathan, Nebykova, Anna, Kerridge, Simon A, Hill, Jennifer, Thomaides-Brears, Helena, Blohmke, Christoph J, Yu, Ly-Mee, Angus, Brian, Pollard, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720597/
https://www.ncbi.nlm.nih.gov/pubmed/28965718
http://dx.doi.org/10.1016/S0140-6736(17)32149-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720597/
https://www.ncbi.nlm.nih.gov/pubmed/28965718
http://dx.doi.org/10.1016/S0140-6736(17)32149-9

Ejemplares similares